TROG Cancer Research
Members Login   CQMS Login

TROG 05.02 MALT Lymphoma

Primary sponsor: TROG
Collaborating groups: Australasian Leukaemia & Lymphoma Group (NH15); Princess Margaret Hospital, Toronto, Canada

Title

Involved Field Radiotherapy for Non-Gastric Marginal Zone Lymphoma

Summary

The main aim of this study is to test the effectiveness of radiotherapy for marginal zone lymphoma that has developed outside the stomach. The treatment that is given in the trial is standard therapy but information on the response to treatment and the side-effects associated with treatment has never been collected before in a large study in which patients all received the same treatment and were closely followed up afterwards.

The second aim of the study is to look at factors that might cause marginal zone lymphoma. Often this type of lymphoma can be associated with infection in the stomach with a bacterium called Helicobacter pylori. Each participant will be tested for the infection using a breath test. Treatment for the infection will be offered if H. pylori infection is found. There have been reports of disappearance of this type of lymphoma just with antibiotic therapy when there has been H. pylori infection in the stomach, even if the lymphoma was growing another part of the body.

Final accrual

70

Trial Status

Closed to Accrual, October 2014 

Trial chairperson

Associate Professor Michael MacManus, Peter MacCallum Cancer Centre, VIC

Trial contact

Marijana Vanevski
Peter MacCallum Cancer Centre (PMCC), Parkville, Melbourne
Email: marijana.vanevski@petermac.org

Further information

TROG 05.02 on Australian Cancer Trials Register

Trial resources for TROG members

TROG 05.02 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.